I'm going to tell you a story that mixes politics, desperate families, Big Pharma, and that same old smoke-and-mirrors act governments love to pull.
On Tuesday, the FDA — America's drug watchdog with a billion-dollar budget — approved leucovorin as the first treatment for a rare genetic disease called cerebral folate deficiency. A condition that affects a tiny sliver of the population, hits kids under 2 years old, and causes severe developmental delays, seizures, and serious neurological complications.
So far, so good. Nice story. Old drug finds a new purpose. But here's the thing — this story has a much louder prologue.
The Trojan Horse Called "Autism"
Months ago, the Trump administration came out blasting the trumpets that leucovorin — a synthetic B9 vitamin that's been around since the '80s, used to counteract the toxic effects of chemo — could be the big breakthrough therapy for a much larger group of patients: children with autism spectrum disorder.
Holy shit, imagine the impact of that.
Entire families, desperate for any spark of hope, rushed to their doctors' offices. Leucovorin prescriptions skyrocketed across the U.S. Doctors were pressured. Pharmacies saw demand explode. The narrative was too good to be true.
And — surprise! — it was too good to be true.
An FDA official, speaking on condition of anonymity, told reporters on Monday the one sentence that sums it all up: "We don't have enough data to establish efficacy for autism broadly."
Translation from regulatory-speak: we sold the steak before we slaughtered the cow.
What Was Actually Approved
Leucovorin was approved for cerebral folate deficiency, a rare genetic mutation that prevents folate from reaching the brain properly. This condition has symptoms that overlap with autism — hence the convenient confusion — but it's a distinct disease, with a tiny patient population.
The FDA admitted it started with a broad review targeting autism and kept narrowing the scope until it landed on this smaller population, where the data showed larger effects. And here's the detail that should make any investor raise an eyebrow: the approval was based on a review of published literature and patient case reports, not a randomized controlled clinical trial.
Yes, you read that right. No randomized trial. The official himself acknowledged that systematic reviews can carry biases, but argued the treatment effects were so large they outweighed those concerns.
It's like saying: "The map might be wrong, but the treasure looked so big we went for it anyway." Nassim Taleb would have a heart attack.
And GSK? They Want No Part of This
The most cinematic part: GSK, which originally marketed the drug under the brand name Wellcovorin from 1983 to 1997, already announced back in September that it has no plans to relaunch or manufacture the product. The approval covers generic versions and the old brand name — but the brand owner left the stage before the show even started.
The FDA is "encouraging" existing leucovorin manufacturers to ramp up production to meet growing demand. Encouraging. Not requiring. Not subsidizing. Encouraging.
If you're an investor looking for the trade here, the answer probably isn't GSK. It might be in generic manufacturers that decide to ride this wave of regulatory-sanctioned demand. But heads up: the ultra-rare disease market is a niche within a niche. The numbers are small.
The Pattern That Keeps Repeating
This story is a masterclass in how politics hijacks science. The Trump administration rode the autism narrative — an emotionally charged topic affecting millions of families — to push an agenda of "we're doing something." When the FDA actually did its homework, the data only supported a tiny fraction of that grand promise.
Tracy Beth Hoeg, acting director of the FDA's Center for Drug Evaluation, said the approval demonstrates a "commitment to rapidly identifying effective treatments for ultra-rare diseases while maintaining the same standards of evidence."
Sounds great in a press release. In practice, they approved it without a randomized trial and based on a literature review.
The question that lingers: when the government sells you hope as if it were certainty, and then science delivers only a small piece of that promise — who picks up the emotional tab for the families that bought the whole dream?
